CareDx, Inc. (CDNA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$50.88+2.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · CDNA
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $51 CDNA trades at 56× p/e — 1.6× the 34× p/e peer median. The market is re-rating it beyond its own range; our $50 fair value is medium-confidence here. Analysts target $35–$65. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $53.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $76.14 | — | — | Analyst | high |
| dcf fcff | 12M | $83.14 | — | — | Analyst | high |
| graham number | 12M | $12.77 | — | — | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$35.00 – $65.00 (median $53.00) · 6 analysts · as of 2026-09-02
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $55.20 |
| 34.7 |
| 1.59 |
| TTM |
| high |
| Peer P/E | 12M | $30.85 | 33.9 | 0.91 | TTM | high |
| Peer P/S | 12M | $48.93 | 5.7 | 8.57 | TTM | high |
| PEG | 12M | $69.68 | 76.6 | 0.91 | TTM | high |
| residual income | 12M | $9.09 | — | — | TTM | high |
| triangulated | 12M | $34.08 | 33.9 | 1.01 | Triangulated | high |
| Peer P/E | 3Y | $44.66 | 33.9 | 1.32 | Analyst | medium |
| Peer P/S | 3Y | $55.78 | 5.7 | 9.77 | guidance | medium |
| PEG | 3Y | $100.86 | 76.6 | 1.32 | Analyst | medium |
| Peer P/E | 5Y | $44.26 | 33.9 | 1.31 | Analyst | medium |
| Peer P/S | 5Y | $55.27 | 5.7 | 9.69 | guidance | medium |
| PEG | 5Y | $99.94 | 76.6 | 1.31 | Analyst | medium |